Wird geladen...

Pharmacodynamic and Efficacy Studies of the Novel Proteasome Inhibitor NPI-0052 (marizomib) in a Human Plasmacytoma Xenograft Murine Model

Our previous study showed that the novel proteasome inhibitor NPI-0052 induces apoptosis in multiple myeloma (MM) cells resistant to conventional and bortezomib (Velcade™) therapies. In vivo studies using human MM-xenografts demonstrated that NPI-0052 is well tolerated, prolongs survival, and reduce...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Br J Haematol
Hauptverfasser: Singh, Ajita V., Palladino, Michael A., Lloyd, G. Kenneth, Potts, Barbara, Chauhan, Dharminder, Anderson, Kenneth C.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2010
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4427841/
https://ncbi.nlm.nih.gov/pubmed/20331453
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2010.08144.x
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!